|
Gene: RPS8 |
Gene summary for RPS8 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RPS8 | Gene ID | 6202 |
Gene name | ribosomal protein S8 | |
Gene Alias | S8 | |
Cytomap | 1p34.1 | |
Gene Type | protein-coding | GO ID | GO:0000462 | UniProtAcc | P62241 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6202 | RPS8 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.63e-88 | 3.16e+00 | -0.1954 |
6202 | RPS8 | HTA11_411_2000001011 | Human | Colorectum | SER | 3.81e-22 | 3.47e+00 | -0.2602 |
6202 | RPS8 | HTA11_2112_2000001011 | Human | Colorectum | SER | 6.06e-10 | 2.66e+00 | -0.2196 |
6202 | RPS8 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.13e-52 | 3.01e+00 | -0.1207 |
6202 | RPS8 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.58e-50 | 3.02e+00 | -0.1526 |
6202 | RPS8 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.24e-99 | 3.38e+00 | -0.1464 |
6202 | RPS8 | HTA11_866_2000001011 | Human | Colorectum | AD | 4.49e-91 | 2.95e+00 | -0.1001 |
6202 | RPS8 | HTA11_1391_2000001011 | Human | Colorectum | AD | 5.32e-89 | 3.74e+00 | -0.059 |
6202 | RPS8 | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.19e-30 | 3.12e+00 | -0.1706 |
6202 | RPS8 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.63e-21 | 2.02e+00 | -0.2061 |
6202 | RPS8 | HTA11_5216_2000001011 | Human | Colorectum | SER | 6.82e-31 | 3.18e+00 | -0.1462 |
6202 | RPS8 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.54e-45 | 3.25e+00 | -0.0842 |
6202 | RPS8 | HTA11_9341_2000001011 | Human | Colorectum | SER | 1.75e-25 | 2.88e+00 | -0.00410000000000005 |
6202 | RPS8 | HTA11_7862_2000001011 | Human | Colorectum | AD | 4.88e-47 | 2.93e+00 | -0.0179 |
6202 | RPS8 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.36e-108 | 3.64e+00 | 0.096 |
6202 | RPS8 | HTA11_4255_2000001011 | Human | Colorectum | SER | 3.17e-39 | 3.77e+00 | 0.0446 |
6202 | RPS8 | HTA11_9408_2000001011 | Human | Colorectum | AD | 1.40e-28 | 2.28e+00 | 0.0451 |
6202 | RPS8 | HTA11_8622_2000001021 | Human | Colorectum | SER | 8.07e-47 | 3.74e+00 | 0.0528 |
6202 | RPS8 | HTA11_7663_2000001011 | Human | Colorectum | SER | 7.70e-39 | 3.65e+00 | 0.0131 |
6202 | RPS8 | HTA11_10623_2000001011 | Human | Colorectum | AD | 2.73e-43 | 3.21e+00 | -0.0177 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
GO:00226139 | Breast | Precancer | ribonucleoprotein complex biogenesis | 79/1080 | 463/18723 | 2.11e-18 | 1.03e-15 | 79 |
GO:00422549 | Breast | Precancer | ribosome biogenesis | 52/1080 | 299/18723 | 7.35e-13 | 1.51e-10 | 52 |
GO:00422749 | Breast | Precancer | ribosomal small subunit biogenesis | 21/1080 | 73/18723 | 4.84e-10 | 4.39e-08 | 21 |
GO:00063646 | Breast | Precancer | rRNA processing | 35/1080 | 225/18723 | 7.90e-08 | 4.60e-06 | 35 |
GO:00160726 | Breast | Precancer | rRNA metabolic process | 36/1080 | 236/18723 | 8.59e-08 | 4.84e-06 | 36 |
GO:00344705 | Breast | Precancer | ncRNA processing | 42/1080 | 395/18723 | 9.91e-05 | 1.83e-03 | 42 |
GO:00346604 | Breast | Precancer | ncRNA metabolic process | 45/1080 | 485/18723 | 1.15e-03 | 1.26e-02 | 45 |
GO:00304902 | Breast | Precancer | maturation of SSU-rRNA | 8/1080 | 50/18723 | 7.39e-03 | 4.90e-02 | 8 |
GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
GO:002261314 | Breast | IDC | ribonucleoprotein complex biogenesis | 83/1434 | 463/18723 | 2.01e-13 | 5.20e-11 | 83 |
GO:004225414 | Breast | IDC | ribosome biogenesis | 52/1434 | 299/18723 | 1.90e-08 | 1.32e-06 | 52 |
GO:004227414 | Breast | IDC | ribosomal small subunit biogenesis | 21/1434 | 73/18723 | 7.23e-08 | 4.42e-06 | 21 |
GO:000636414 | Breast | IDC | rRNA processing | 35/1434 | 225/18723 | 4.59e-05 | 1.03e-03 | 35 |
GO:001607214 | Breast | IDC | rRNA metabolic process | 36/1434 | 236/18723 | 5.48e-05 | 1.17e-03 | 36 |
GO:000218124 | Breast | DCIS | cytoplasmic translation | 82/1390 | 148/18723 | 2.21e-53 | 1.25e-49 | 82 |
GO:002261324 | Breast | DCIS | ribonucleoprotein complex biogenesis | 83/1390 | 463/18723 | 3.65e-14 | 1.09e-11 | 83 |
GO:004225423 | Breast | DCIS | ribosome biogenesis | 52/1390 | 299/18723 | 6.73e-09 | 5.44e-07 | 52 |
GO:004227424 | Breast | DCIS | ribosomal small subunit biogenesis | 21/1390 | 73/18723 | 4.24e-08 | 2.67e-06 | 21 |
GO:000636422 | Breast | DCIS | rRNA processing | 35/1390 | 225/18723 | 2.41e-05 | 5.62e-04 | 35 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPS8 | SNV | Missense_Mutation | c.213T>G | p.Cys71Trp | p.C71W | P62241 | protein_coding | tolerated(0.1) | possibly_damaging(0.84) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RPS8 | deletion | Frame_Shift_Del | c.427delN | p.Ile145PhefsTer46 | p.I145Ffs*46 | P62241 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
RPS8 | SNV | Missense_Mutation | novel | c.275G>A | p.Arg92His | p.R92H | P62241 | protein_coding | deleterious(0.02) | possibly_damaging(0.741) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
RPS8 | SNV | Missense_Mutation | c.392N>A | p.Pro131His | p.P131H | P62241 | protein_coding | deleterious(0.03) | benign(0.057) | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
RPS8 | SNV | Missense_Mutation | novel | c.405N>T | p.Glu135Asp | p.E135D | P62241 | protein_coding | tolerated(0.25) | benign(0.007) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RPS8 | SNV | Missense_Mutation | novel | c.614N>A | p.Arg205His | p.R205H | P62241 | protein_coding | deleterious(0.01) | benign(0.088) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RPS8 | SNV | Missense_Mutation | c.391C>T | p.Pro131Ser | p.P131S | P62241 | protein_coding | tolerated(0.08) | benign(0.043) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RPS8 | SNV | Missense_Mutation | novel | c.5N>A | p.Gly2Asp | p.G2D | P62241 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPS8 | SNV | Missense_Mutation | novel | c.195C>A | p.Phe65Leu | p.F65L | P62241 | protein_coding | deleterious(0) | possibly_damaging(0.558) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
RPS8 | SNV | Missense_Mutation | c.220N>T | p.Arg74Cys | p.R74C | P62241 | protein_coding | tolerated(0.15) | benign(0.082) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |